ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

China will accept foreign clinical trial data

Decision by country’s drug administrator should help foreign drug companies

by Jean-François Tremblay
October 11, 2017 | APPEARED IN VOLUME 95, ISSUE 41

Credit: Jean-François Tremblay/C&EN
Chinese citizens should get access to more foreign drugs following a change in policy about clinical trials.

In a move likely to benefit Chinese citizens as well as foreign drug firms, the Chinese government has agreed to accept data from clinical trials conducted outside China for the approval of new drugs.

“Applicants can directly apply for drug listing registration after the completion of the international multicenter drug clinical trials,” the China Food & Drug Administration (CFDA) disclosed in a statement.

Until now, China only approved drugs that had been tested on people in China. And foreign firms could start testing in China only after they had demonstrated the safety of their drug with tests conducted overseas.

This meant that Chinese people gained access to innovative new drugs years after they had been approved overseas—if ever. In the past, many major drug companies did not bother to launch their drugs in China because of the cost and delay involved. By the time foreign-developed drugs gained approval, competing versions were often already available from Chinese firms.

CFDA has been reforming its drug registration process for several years. The agency earlier hired more reviewers to reduce its drug approval backlog. It also warned companies registering drugs in China to withdraw their applications—or face administrative sanctions—if they had doubts about the authenticity of their clinical trial data. The warning helped to reduce the number of applications that the agency had to review.

IMS Health, a market research firm, expects that China will account for 11% of global pharmaceutical spending by 2020. The country is already the world’s second-largest drug market after the U.S.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment